The gut microbiota of people with asthma influences lung inflammation in gnotobiotic mice

The gut microbiota in early childhood is linked to asthma risk, but may continue to affect older patients with asthma. Here, we profile the gut microbiota of 38 children (19 asthma, median age 8) and 57 adults (17 asthma, median age 28) by 16S rRNA sequencing and find individuals with asthma harbored compositional differences from healthy controls in both adults and children. We develop a model to aid the design of mechanistic experiments in gnotobiotic mice and show enterotoxigeni

Airway microbiota-host interactions regulate secretory leukocyte protease inhibitor levels and influence allergic airway inflammation

Homeostatic mucosal immune responses are fine-tuned by naturally evolved interactions with native microbes, and integrating these relationships into experimental models can provide new insights into human diseases. Here, we leverage a murine-adapted airway microbe, Bordetella pseudohinzii (Bph), to investigate how chronic colonization impacts mucosal immunity and the development of allergic airway inflammation (AAI). Colonization with Bph induces the differentiation of interleukin-17A (IL-17A)-secreting T-helper cells that aid in controlling bacterial abundance. Bph colonization protects from AAI and is associated with increased production of secretory leukocyte protease inhibitor (SLPI), an antimicrobial peptide with anti-inflammatory properties. These findings are additionally supported by clinical data showing that higher levels of upper respiratory SLPI correlate both with greater asthma control and the presence of Haemophilus, a bacterial genus associated with AAI. We propose that SLPI could be used as a biomarker of beneficial host-commensal relationships in the airway

Alu-folija i njezin utjecaj na trajnost topljenog sira

Nije rijetkost da se proizvođačima topljeni sir stavlja na raspolaganje, tj. vraća iz trgovačke mreže. To je vrlo često osjetljivi gubitak za proizvođača, dok potrošač gubi povjerenje te izbjegava trošenje ove vrsti sira

The TEMPO Survey I: Predicting Yields of the Transiting Exosatellites, Moons, and Planets from a 30-day Survey of Orion with the Nancy Grace Roman Space Telescope

We present design considerations for the Transiting Exosatellites, Moons, and Planets in Orion (TEMPO) Survey with the Nancy Grace Roman Space Telescope. This proposed 30-day survey is designed to detect a population of transiting extrasolar satellites, moons, and planets in the Orion Nebula Cluster (ONC). The young (1-3 Myr), densely-populated ONC harbors about a thousand bright brown dwarfs (BDs) and free-floating planetary-mass objects (FFPs). TEMPO offers sufficient photometric precision to monitor FFPs with ${\rm M}\geq1{\rm M}_{\rm J}$ for transiting satellites. The survey is also capable of detecting FFPs down to sub-Saturn masses via direct imaging, although follow-up confirmation will be challenging. TEMPO yield estimates include 14 (3-22) exomoons/satellites transiting FFPs and 54 (8-100) satellites transiting BDs. Of this population, approximately $50\%$ of companions would be "super-Titans" (Titan to Earth mass). Yield estimates also include approximately $150$ exoplanets transiting young Orion stars, of which $>50\%$ will orbit mid-to-late M dwarfs and approximately ten will be proto-habitable zone, terrestrial ($0.1{\rm M}_{\oplus} - 5{\rm M}_{\oplus}$) exoplanets. TEMPO would provide the first census demographics of small exosatellites orbiting FFPs and BDs, while simultaneously offering insights into exoplanet evolution at the earliest stages. This detected exosatellite population is likely to be markedly different from the current census of exoplanets with similar masses (e.g., Earth-mass exosatellites that still possess H/He envelopes). Although our yield estimates are highly uncertain, as there are no known exoplanets or exomoons analogous to these satellites, the TEMPO survey would test the prevailing theories of exosatellite formation and evolution, which limit the certainty surrounding detection yields.Comment: Submitted to PAS

The mortality after release from incarceration consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis

Introduction More than 30 million adults are released from incarceration globally each year. Many experience complex physical and mental health problems, and are at markedly increased risk of preventable mortality. Despite this, evidence regarding the global epidemiology of mortality following release from incarceration is insufficient to inform the development of targeted, evidence-based responses. Many previous studies have suffered from inadequate power and poor precision, and even large studies have limited capacity to disaggregate data by specific causes of death, sub-populations or time since release to answer questions of clinical and public health relevance. Objectives To comprehensively document the incidence, timing, causes and risk factors for mortality in adults released from prison. Methods We created the Mortality After Release from Incarceration Consortium (MARIC), a multi-disciplinary collaboration representing 29 cohorts of adults who have experienced incarceration from 11 countries. Findings across cohorts will be analysed using a two-step, individual participant data meta-analysis methodology. Results The combined sample includes 1,337,993 individuals (89% male), with 75,795 deaths recorded over 9,191,393 person-years of follow-up. Conclusions The consortium represents an important advancement in the field, bringing international attention to this problem. It will provide internationally relevant evidence to guide policymakers and clinicians in reducing preventable deaths in this marginalized population

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

BACKGROUND: Microarray-based gene expression profiling is a powerful approach for the identification of molecular biomarkers of disease, particularly in human cancers. Utility of this approach to measure responses to therapy is less well established, in part due to challenges in obtaining serial biopsies. Identification of suitable surrogate tissues will help minimize limitations imposed by those challenges. This study describes an approach used to identify gene expression changes that might serve as surrogate biomarkers of drug activity. METHODS: Expression profiling using microarrays was applied to peripheral blood mononuclear cell (PBMC) samples obtained from patients with advanced colorectal cancer participating in a Phase III clinical trial. The PBMC samples were harvested pre-treatment and at the end of the first 6-week cycle from patients receiving standard of care chemotherapy or standard of care plus SU5416, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor. Results from matched pairs of PBMC samples from 23 patients were queried for expression changes that consistently correlated with SU5416 administration. RESULTS: Thirteen transcripts met this selection criterion; six were further tested by quantitative RT-PCR analysis of 62 additional samples from this trial and a second SU5416 Phase III trial of similar design. This method confirmed four of these transcripts (CD24, lactoferrin, lipocalin 2, and MMP-9) as potential biomarkers of drug treatment. Discriminant analysis showed that expression profiles of these 4 transcripts could be used to classify patients by treatment arm in a predictive fashion. CONCLUSIONS: These results establish a foundation for the further exploration of peripheral blood cells as a surrogate system for biomarker analyses in clinical oncology studies